Keylika
Redefining the Standard of Care for Iron Deficiency Anemia
About
Keylika is an early stage biopharma startup developing metal-based drugs using a platform synthesis technology to treat unmet medical needs. We then administer these drugs using proven delivery technologies to effect the best clinical outcomes. Our first product is a small molecule iron drug (new molecular entity) delivered by a wearable skin patch to treat Iron Deficiency Anemia (IDA), with significantly higher safety, efficacy and tolerability over existing treatments. This is poised to be a best-in-class, potentially breakthrough therapy for treating iron deficiency without any GI side-effects (eg. nausea, constipation, diarrhea, etc.) typically associated with oral iron supplements, and without the risks, costs and side-effects associated with IV iron infusions. When approved, Keylika’s proprietary transdermal iron will be the world's first prescription iron patch. Iron deficiency is a hugely understated problem affecting about 1.6 billion people worldwide and more than 30 million in the US alone, translating to a $17B US market. Keylika is a Y Combinator company (Summer 2022). YC-listed status: Active.
- Website
- keylika.com
- Location
- San Francisco, CA, USA; Walnut Creek, CA, USA
- Added via
- web
- Ownership
- unclaimed
Where to go
Products
- NistuFe — Prescription transdermal skin patch delivering a proprietary iron compound to the bloodstream to treat iron deficiency anemia without GI side effects. · Other
Links
- Y Combinator profileycombinator